DNTH insider transaction filings
Dianthus Therapeutics, Inc. /DE/ — 48 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen DNTH transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Read Simon — Director | Option exercise (M): 2,778 @ $18.36 · Sale (S): 2,778 @ $117.55 · Option exercise (M): 2,778 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Option exercise (M): 15,000 @ $18.17 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | McGeorge Anne — Director | Option exercise (M): 1,250 @ $19.36 · Option exercise (M): 6,500 @ $11.20 · Sale (S): 1,450 @ $107.58 · Sale (S): 2,800 @ $108.38 · Sale (S): 1,800 @ $109.30 · Sale (S): 1,000 @ $110.64 · +3 more | EDGAR |
| 2026-08-11 | 4 | Read Simon — Director | Option exercise (M): 2,777 @ $18.36 · Sale (S): 70 @ $107.11 · Sale (S): 737 @ $108.17 · Sale (S): 831 @ $108.95 · Sale (S): 272 @ $109.96 · Sale (S): 470 @ $111.05 · +2 more | EDGAR |
| 2026-08-11 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Option exercise (M): 3,833 @ $17.88 · Sale (S): 3,217 @ $110.61 · Sale (S): 616 @ $111.18 · Option exercise (M): 16,167 @ $17.88 · Sale (S): 16,167 @ $110.38 · Option exercise (M): 3,833 (derivative) @ $0 · +1 more | EDGAR |
| 2026-08-07 | 4 | Garcia Marino — CEO AND PRESIDENT, Director | Option exercise (M): 40,000 @ $8.44 · Option exercise (M): 126,000 @ $8.44 · Sale (S): 10,384 @ $107.49 · Sale (S): 23,907 @ $108.05 · Sale (S): 2,373 @ $109.10 · Sale (S): 2,536 @ $110.02 · +5 more | EDGAR |
| 2026-07-13 | 4 | Savitz Ryan — EVP, CFO & CBO | Option exercise (M): 31,249 @ $21.77 · Sale (S): 10,354 @ $100.22 · Sale (S): 15,329 @ $101.24 · Sale (S): 5,566 @ $101.97 · Option exercise (M): 31,249 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Option exercise (M): 30,000 @ $17.88 · Sale (S): 16,771 @ $80.34 · Sale (S): 13,229 @ $81.38 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Randhawa Simrat — EVP, Head of R&D | Option exercise (M): 3,998 @ $8.44 · Option exercise (M): 6,908 @ $17.88 · Option exercise (M): 6,249 @ $21.77 · Option exercise (M): 9,375 @ $22.07 · Sale (S): 5,428 @ $89.72 · Sale (S): 16,943 @ $90.72 · +5 more | EDGAR |
| 2026-05-22 | 4 | McGeorge Anne — Director | Grant/award (A): 6,090 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Violin Jonathan — Director | Grant/award (A): 6,090 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Soteropoulos Paula — Director | Grant/award (A): 6,090 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Read Simon — Director | Grant/award (A): 6,090 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Romano Steven J. — Director | Grant/award (A): 6,090 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Lawton Alison Frances — Director | Grant/award (A): 6,090 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | KANGO SUJAY — Director | Grant/award (A): 6,090 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Soteropoulos Paula — Director | Option exercise (M): 599 @ $8.44 · Sale (S): 599 @ $85.47 · Option exercise (M): 599 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Savitz Ryan — EVP, CFO & CBO | Option exercise (M): 8,224 @ $17.88 · Sale (S): 8,224 @ $89.84 · Option exercise (M): 8,224 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Savitz Ryan — EVP, CFO & CBO | Option exercise (M): 74,367 @ $8.44 · Option exercise (M): 40,000 @ $17.88 · Sale (S): 1,390 @ $78.33 · Sale (S): 21,825 @ $78.86 · Sale (S): 1,485 @ $80.25 · Sale (S): 800 @ $81.36 · +6 more | EDGAR |
| 2026-04-01 | 4 | Soteropoulos Paula — Director | Option exercise (M): 599 @ $8.44 · Sale (S): 599 @ $80.11 · Option exercise (M): 599 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Soteropoulos Paula — Director | Option exercise (M): 27,594 @ $8.44 · Sale (S): 27,594 @ $78.05 · Option exercise (M): 27,594 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Garcia Marino — CEO AND PRESIDENT, Director | Option exercise (M): 59,700 @ $6.70 · Option exercise (M): 5,592 @ $17.88 · Option exercise (M): 59,700 (derivative) @ $0 · Option exercise (M): 5,592 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Randhawa Simrat — EVP, Head of R&D | Option exercise (M): 7,998 @ $8.44 · Option exercise (M): 5,000 @ $17.88 · Option exercise (M): 8,332 @ $21.77 · Option exercise (M): 12,500 @ $22.07 · Sale (S): 33,830 @ $81.48 · Option exercise (M): 7,998 (derivative) @ $0 · +3 more | EDGAR |
| 2026-03-13 | 4 | Garcia Marino — CEO AND PRESIDENT, Director | Option exercise (M): 122,918 @ $6.70 · Sale (S): 43,505 @ $80.69 · Sale (S): 65,517 @ $81.74 · Sale (S): 12,796 @ $82.60 · Sale (S): 200 @ $83.38 · Sale (S): 900 @ $85.53 · +1 more | EDGAR |
| 2026-03-13 | 4 | CARR EDWARD — CHIEF ACCOUNTING OFFICER | Option exercise (M): 16,182 @ $17.88 · Option exercise (M): 17,500 @ $22.07 · Option exercise (M): 10,000 @ $21.77 · Sale (S): 15,852 @ $80.71 · Sale (S): 23,465 @ $81.75 · Sale (S): 3,865 @ $82.66 · +5 more | EDGAR |
| 2026-02-04 | 4 | Savitz Ryan — EVP, CFO & CBO | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Randhawa Simrat — EVP, Head of R&D | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Garcia Marino — CEO AND PRESIDENT, Director | Grant/award (A): 355,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | CARR EDWARD — CHIEF ACCOUNTING OFFICER | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Savitz Ryan — CFO & CBO | Option exercise (M): 20,000 @ $8.44 · Sale (S): 20,000 @ $45.18 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Randhawa Simrat — EVP, Head of R&D | Option exercise (M): 83,978 @ $8.44 · Option exercise (M): 3,529 @ $17.88 · Sale (S): 26,166 @ $35.80 · Sale (S): 42,765 @ $37.04 · Sale (S): 18,576 @ $37.72 · Option exercise (M): 40,287 @ $17.88 · +8 more | EDGAR |
| 2025-10-03 | 4 | Garcia Marino — CEO AND PRESIDENT, Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-09-25 | 4 | Savitz Ryan — CFO & CBO | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-09-25 | 4 | Randhawa Simrat — CHIEF MEDICAL OFFICER | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | Savitz Ryan — CFO & CBO | Option exercise (M): 20,000 @ $8.44 · Sale (S): 20,000 @ $35 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Violin Jonathan — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Soteropoulos Paula — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | McGeorge Anne — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Read Simon — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Romano Steven J. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Lawton Alison Frances — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | KANGO SUJAY — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Randhawa Simrat — CHIEF MEDICAL OFFICER | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Savitz Ryan — CFO & CBO | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Garcia Marino — CEO AND PRESIDENT, Director | Grant/award (A): 340,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | CARR EDWARD — CHIEF ACCOUNTING OFFICER | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Dianthus Therapeutics, Inc. /DE/
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DNTH returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →